$0.93
−2.06%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.98
From 52W high−85.09%
Volume15794.00
Market cap$3.71M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.98
From 52W high
−85.09%
Volume
15794.00
Market cap
$3.71M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
P/E (TTM)
—
RSI (14)
42.6
MomentumView details →
1D Return
−2.06%
YTD Return
−70.06%
SummaryUpdated Jun 1, 2026
Revelation Biosciences, Inc. (NASDAQ:REVB) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in San Diego, California. The company went public in November 2020 and focuses on developing immune system therapeutics and diagnostics. As a relatively young biotech firm, Revelation operates without current revenue generation, dedicating its resources entirely to research and development of novel therapeutic candidates across multiple disease areas including respiratory conditions, chronic organ diseases, and infectious disease diagnostics.
Similar companies
Latest newsMore news →
Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 TITAN study evaluating Gemini in patients with acute kidney injury.32d agoRevelation Biosciences, Inc. granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont III as part of their compensation.33d ago